The Characterized Cell Line core (CCLC) was established in 2008 with the purpose of preserving and distributing cell lines developed at MD Anderson. The initial focus was on providing well-characterized cell lines so that researchers could choose the correct cell line for their research. Services were expanded almost immediately to include human cell line validation and Mycoplasma testing. Cell line validation is done by short tandem repeats (STR) profiling. To avoid duplicating equipment and effort, the polymerase chain reaction (PCR) fragmentation reactions are run by the Sequencing and Microarray Facility on an Applied Biosystems 3730 XL genetic analyzer. The CCLC has developed a novel STR matching algorithm that can take into account variations due to cell line cross-contamination and to genomic instability. CCLC has also established a proprietary database with STR profiles from over 1000 unique cell lines as well as over 2000 public STR profiles. The CCLC also offers mutational analysis of human cell lines as another method to ensure cell line authenticity. Mutational analysis is done using a Sequenom MassARRAY, which runs a primer extension based method to determine sequence information on a single base. The CCLC has developed a custom somatic mutation panel enabling incorporation of new somatic mutations as they are published in the literature, rather than waiting for a new somatic mutational panel from Sequenom. The CCLC also offers custom-designed panels. Since 2008, the CCLC has been used by 128 Center members, representing all 19 CCSG programs. The institution has supported this core with funding of $99,692 for capital equipment, including incubators, a -80? C freezer, PCR machines, a plate reader, and a Qiacube robot. The CCLC has facilitated publication of 53 reports since 2008, with 58% in journals with an impact score >5 and 15% in journals with an impact factor >10. Publications cited using the CCLC have appeared in several high impact journals such as Nat Gen, Cell, Cancer Cell and J Natl Cancer Inst. Peer-reviewed investigators account for 91% of the utilization, and 34% of the total costs are requested from the CCSG. This will enable expansion of services and additional testing of cell lines to identify cross-contamination between species as well as to test for potential virus contamination. Future work will focus on expanding the number of cell lines available to MD Anderson researchers, expanding characterization of cell lines to include whole genome/exome sequencing approaches, and improving methods to detected cross contamination especially intra-species cross-contamination.

Public Health Relevance

Cell line authentication is now a requirement at MD Anderson for all research using cell lines. This requirement is in place so that data generated here can be of the highest quality. The CCLC not only helps ensure that MD Anderson researchers have the tools to test their cell lines but also assists in characterizing any newly established cell lines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759787
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$137,635
Indirect Cost
$51,650
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Echeverria, Gloria V; Powell, Emily; Seth, Sahil et al. (2018) High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun 9:5079
Smith, Brian; Hsu, Yi-Hsin; Flores, Rene et al. (2018) Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy. Am J Cancer Res 8:183-191
Kuerer, Henry M; Rauch, Gaiane M; Krishnamurthy, Savitri et al. (2018) A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg 267:946-951
Tamari, Roni; Oran, Betul; Hilden, Patrick et al. (2018) Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1079-1087
Khalaf, Ahmed M; Fuentes, David; Morshid, Ali I et al. (2018) Role of Wnt/?-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma 5:61-73
Horvath, Thomas D; Dagan, Shai; Lorenzi, Philip L et al. (2018) Positional stable isotope tracer analysis reveals carbon routes during ammonia metabolism of Aedes aegypti mosquitoes. FASEB J 32:466-477
Yang, Wei T; Parikh, Jay R; Stavros, A Thomas et al. (2018) Exploring the Negative Likelihood Ratio and How It Can Be Used to Minimize False-Positives in Breast Imaging. AJR Am J Roentgenol 210:301-306
Tetzlaff, M T; Messina, J L; Stein, J E et al. (2018) Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol 29:1861-1868
Yan, Xiaoyu; Clemens, Pamela L; Puchalski, Thomas et al. (2018) Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet 57:529-538
Jacobs, Daniel I; Liu, Yanhong; Gabrusiewicz, Konrad et al. (2018) Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol 136:33-39

Showing the most recent 10 out of 12418 publications